Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

115
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

10.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
10.7K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer Survival Analysis01:21

Cancer Survival Analysis

324
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
324

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement.

Cardio-oncology (London, England)·2026
Same author

Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio‑Oncology Society (IC‑OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Dyslipidaemias in cancer patients.

European heart journal·2026
Same author

Cancer and cardiovascular disease: converging burdens, shared challenges.

European heart journal·2026
Same author

Multimodality imaging in the detection and management of coronary and peripheral arterial disease in patients with cancer receiving cardiotoxic antineoplastic treatments: A clinical consensus statement of the ESC Council of Cardio-Oncology and the European Association of Cardiovascular Imaging (EACVI) of the ESC.

European heart journal. Cardiovascular Imaging·2026
Same author

Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers.

Cancer medicine·2026

Related Experiment Video

Updated: May 30, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.7K

Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps.

Jieli Tong1,2, Isabelle Senechal1, Sivatharshini Ramalingam1

  • 1Cardio-Oncology Centre of Excellence, Royal Brompton Hospital, London, UK.

British Journal of Hospital Medicine (London, England : 2005)
|January 25, 2025
PubMed
Summary

Cardiovascular disease risk in cancer patients is rising. This review offers a 7-step guide for physicians to evaluate cardiac risk before cancer treatment, aiding early detection and personalized care.

Keywords:
anti-cancer therapycardio-oncologycardiotoxicityguiderisk stratification

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.4K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K

Related Experiment Videos

Last Updated: May 30, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.7K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.4K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K

Area of Science:

  • Cardio-Oncology
  • Cardiovascular Medicine
  • Oncology

Background:

  • Cardiovascular (CV) diseases and cancer treatment cardiotoxicity are increasing concerns.
  • European Society of Cardiology (ESC) 2022 guidelines emphasize standardized risk stratification for cardiotoxicity.
  • The Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) tool is crucial for pre-treatment risk assessment.

Purpose of the Study:

  • To summarize key points of cardiac risk stratification in oncology patients.
  • To provide a simple 7-step guide for general physicians.
  • To aid in evaluating risks associated with potentially cardiotoxic oncologic treatments.

Main Methods:

  • Review of European Society of Cardiology (ESC) 2022 Cardio-Oncology guidelines.
  • Summarization of risk stratification steps for cardiotoxicity.
  • Inclusion of validation data in patients receiving specific therapies (anthracyclines, HER2-targeted, BCR-ABL inhibitors).

Main Results:

  • Baseline CV risk assessment identifies cardiotoxicities early.
  • Stratification allows for personalized cancer treatment and monitoring.
  • Cardioprotection can be allocated to high-risk individuals.

Conclusions:

  • A systematic approach to cardiac risk evaluation is essential for patients undergoing potentially cardiotoxic cancer therapies.
  • The 7-step guide facilitates navigation of cardiac risk assessment.
  • Proactive risk management improves patient outcomes in cardio-oncology.